2025 Updates in Rheumatology

At the conclusion of this activity, the participants should be better able to:

1. Describe diagnostic approaches to rheumatic diseases and their systemic manifestations.
2. Identify systemic manifestations of rheumatic diseases.
3. Summarize current treatment and management approaches for rheumatic diseases.
4. Discuss the role of novel therapies and therapeutic innovations in improving patient outcomes.

Physicians

The University of Nebraska Medical Center designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

4.5 Contact Hours Awarded
Nebraska Medicine is approved as a provider of nursing continuing professional development by the Midwest Multistate Division, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

Read the UNMC CCE Disclosure Declaration Policy 

Disclosures

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

FACULTY

The following have disclosed relevant financial relationships:

• Bryant R. England, MD, PhD*
  Authorship: Elsevier, UpToDate
  Consultant: Boehringer Ingelheim International GmbH
  Honoraria: American College of Rheumatology
• Maximilian F. Konig, MD
  Consultant: Allogene Therapeutics, Argenx, Revel Pharmaceuticals, Sana Biotechnology, Sanofi
  Scientific Advisory Board: Allogene Therapeutics, Sana Biotechnology
  INVESTIGATIONAL/OFF-LABEL USE OF DRUGS DISCLOSURES
  Off-label drug discussions of Blinatumomab and Teclistamab for use in rheumatic diseases
  Off-label drug discussion of various CART-T cell products used for rheumatic diseases
• James R. O'Dell, MD, MACR, MACP*
  Editor: Firestein & Kelley's Textbook of Rheumatology, UpToDate
  Honoraria: American College of Rheumatology
• Sara K. Tedeschi, MD, MPH
  Consultant: Avalo Therapeutics, Inc.; Fresenius Kabi, LLC; Kyowa Kirin Co., Ltd.; Merck & Co.; Novartis Pharmaceuticals Corporation

The following faculty members have nothing to disclose:

• April L. Barnado, MD, MSCI
• Scott M. Matson, MD
• Jennifer L. Medlin, MD
• Austin M. Wheeler, MD

PLANNING COMMITTEE

The following planning committee members have nothing to disclose:

• Tori Greenlee
• Mark Law, PhD
• Jacqueline Siebels, BSN, RN, NPD-BC
• Shannan Wilson, RRT

*Faculty and planning committee members

The following materials (in PDF) are available for download until May 15, 2025. No part of these materials may be reproduced without prior written permission.

• Calcium Pyrophosphate Deposition Disease (CPPD): An Understudied Arthritis That's Moving Forward
  Sara K. Tedeschi, MD, MPH
• Autoimmune Lung Disease: Screening and Monitoring Modalities, a Pulmonologist's Perspective
  Scott M. Matson, MD
• The Present and Future of Immune Effector Cell Therapies in Rheumatology
  Maximilian F. Konig, MD
• Leveraging Predictive Risk Models to Navigate the Diagnostic Challenges of Positive Antinuclear Antibodies
  April L. Barnado, MD, MSCI